U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Addendum to Psychosis and schizophrenia in children and young people. London: National Institute for Health and Care Excellence (NICE); 2016 May. (Clinical Guideline Addendum, No. 155.1.)

Cover of Addendum to Psychosis and schizophrenia in children and young people

Addendum to Psychosis and schizophrenia in children and young people.

Show details

3References

  1. Arango,C., Robles,O., Parellada,M., Fraguas,D., Ruiz-Sancho,A., Medina,O., Zabala,A., Bombín,I., Moreno,D., Olanzapine compared to quetiapine in adolescents with a first psychotic episode, European child & adolescent psychiatry, 18, 418–428, 2009 (included in CG155) [PubMed: 19198920]
  2. Arango,C., Giraldez,M., Merchan-Naranjo,J., Baeza,I., Castro-Fornieles,J., Alda,J.-A., Martinez-Cantarero,C., Moreno,C., De,Andres P., Cuerda,C., De La Serna,E., Correll,C.U., Fraguas,D., Parellada,M., Second-generation antipsychotic use in children and adolescents: A six-month prospective cohort study in drug-naive patients, Journal of the American Academy of Child and Adolescent Psychiatry.53 (11) (pp 1179–1190.e4), 2014.Date of Publication: 2014., 1179–1190, 2014 [PubMed: 25440308]
  3. Carbon,M., Kapoor,S., Sheridan,E., Al-Jadiri,A., Azzo,S., Sarkaria,T., Kane,J.M., Saito,E., Correll,C.U., Neuromotor Adverse Effects in 342 Youth during 12 Weeks of Naturalistic Treatment with 5 Second-Generation Antipsychotics, Journal of the American Academy of Child and Adolescent Psychiatry.54 (9) (pp 718–727), 2015.Date of Publication: 01 Sep 2015., 718–727, 2015 [PMC free article: PMC10366711] [PubMed: 26299293]
  4. Castro-Fornieles,J., Parellada,M., Soutullo,C.A., Baeza,I., Gonzalez-Pinto,A., Graell,M., Paya,B., Moreno,D., Serna,E., Arango,C., Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach, Journal of child and adolescent psychopharmacology, 18, 327–336, 2008 (included in CG155) [PubMed: 18759642]
  5. Correll, C. U., Manu, P., Olshanskiy, V., et al. (2009) Cardiometabolic risk of second-generation antipsychotic medications during fi rst-time use in children and adolescents. Journal of the American Medical Association, 302, 1765–1773 (included in CG155) [PMC free article: PMC3055794] [PubMed: 19861668]
  6. Crocq, MA., Guillon, MS., Bailey, PE., Provost, D., Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. 22, 453–454, 2007 (included in CG155) [PubMed: 17761403]
  7. Kumra,S., Kranzler,H., Gerbino-Rosen,G., Kester,H.M., Thomas,C., Kafantaris,V., Correll,C.U., Kane,J.M., Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison, Biological psychiatry, 63, 524–529, 2008 (included in CG155) [PubMed: 17651705]
  8. Montes,J.M., Ciudad,A., Gascón,J., Gómez,J.C., Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study, Progress in neuro-psychopharmacology & biological psychiatry, 27, 667–674, 2003 [PubMed: 12787855]
  9. Mozes,T., Ebert,T., Michal,S.E., Spivak,B., Weizman,A., An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia, Journal of child and adolescent psychopharmacology, 16, 393–403, 2006 (included in CG155) [PubMed: 16958565]
  10. Noguera,A., Ballesta,P., Baeza,I., Arango,C., De La Serna,E., Gonzalez-Pinto,A., Parellada,M., Graell,M., Moreno,C., Otero,S., Castro-Fornieles,J., Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: Discontinuation and tolerability, Journal of Clinical Psychopharmacology.33 (4) (pp 463–471), 2013.Date of Publication: August 2013., 463–471, 2013 [PubMed: 23771198]
  11. Shaw,P., Sporn,A., Gogtay,N., Overman,G.P., Greenstein,D., Gochman,P., Tossell,J.W., Lenane,M., Rapoport,J.L., Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison, Archives of general psychiatry, 63, 721–730, 2006 (included in CG155) [PubMed: 16818861]
  12. Sikich,L., Hamer,R.M., Bashford,R.A., Sheitman,B.B., Lieberman,J.A., A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 29, 133–145, 2004 (included in CG155) [PubMed: 14583740]
  13. Sikich,L., Frazier,J.A., McClellan,J., Findling,R.L., Vitiello,B., Ritz,L., Ambler,D., Puglia,M., Maloney,A.E., Michael,E., Jong,S., Slifka,K., Noyes,N., Hlastala,S., Pierson,L., McNamara,N.K., Delporto-Bedoya,D., Anderson,R., Hamer,R.M., Lieberman,J.A., Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study, The American journal of psychiatry, 165, 1420–1431, 2008 (included in CG155) [PubMed: 18794207]
Copyright © National Institute for Health and Care Excellence 2016.
Bookshelf ID: NBK550759
Contents